Acute Myeloid Leukemia Clinical Trials

A listing of Acute Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone

acute myeloid leukemia
anthracyclines
cancer
heart problems
blood count
  • 0 views
  • 2 annotations
  • 19 Feb, 2024
Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

A prospective, single-arm, multicenter, exploratory study to evaluate the efficacy and safety of D-CLAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

nephropathy
cytarabine
idarubicin
decitabine
remission
  • 0 views
  • 19 Feb, 2024
Flu-Bu-Mel Conditioning Regimen for Myeloid Disease

For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing allo-HSCT, the conditioning regimen will be 5-day Fludarabine, 2-day Busulifan and 2-day melphalan

  • 0 views
  • 19 Feb, 2024
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

Patients eligible for this study have a type of blood cancer Acute Myeloid Leukemia (AML) which has come back or has not gone away after treatment. The body has different ways of

immunohistochemistry
cancer
aptt
leukemia
myeloid leukemia
  • 0 views
  • 19 Feb, 2024
Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients

This study evaluates Idarubicin (IDA) in combination with the intermediate-dose cytarabine, compared with intermediate-dose cytarabine alone, as a consolidation treatment for elderly AML in

myocardial infarction
idarubicin
anthracyclines
cytarabine
remission
  • 0 views
  • 19 Feb, 2024
Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening

This is a multi center two-stage, two-arm, open label phase II study of venetoclax in combination with azacytidine in acute myeloid leukemia patients selected for therapy with ex vivo venetoclax

acute myeloid leukemia
graft versus host disease
anthracyclines
HIV Infection
remission
  • 0 views
  • 19 Feb, 2024
Healthy Test study

This is a multi center two-stage, two-arm, open label phase II study of venetoclax in combination with azacytidine in acute myeloid leukemia patients selected for therapy with ex vivo venetoclax

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Treatment options for older adults with Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) are limited. Although stem cell transplantation remains one of the most effective treatments it is

fludarabine
kidney function test
acute myeloid leukemia
pulmonary function test
recurrent disease
  • 0 views
  • 19 Feb, 2024
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS CMML or AML

Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose …

thrombocytopenia
acute myeloid leukemia
graft versus host disease
myelodysplastic syndrome
immunosuppressive agents
  • 0 views
  • 19 Feb, 2024
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

This is a single arm study to evaluate the efficacy and safety of CD123-targeted CAR-T cells therapy for patients with relapsed/refractory Acute Myeloid Leukemia.

oxygen saturation
acute myeloid leukemia
refractory aml
remission
chemotherapy regimen
  • 0 views
  • 19 Feb, 2024